This is an entirely free service. No payments are to be made. Also send me The Ultimate Guide to Profiting From Derivatives and sign me up for Profit Hunter,a free newsletter that focuses on identifying short term money making opportunities.Download NowSubscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.

At the closing bell, the BSE Sensex stood lower by 156 points (down 0.4%) and the NSE Nifty closed down by 61 points (down 0.6%). The BSE Mid Cap index ended the day down 0.3%, while the BSE Small Cap index ended the day up by 0.1%.

Asian stock markets finished in red. As of the most recent closing prices, the Hang Seng was down by 0.1% and the Shanghai Composite was down by 0.7%. The Nikkei 225 was down by 0.4%. Meanwhile, European markets, were trading mixed. The FTSE 100 was up by 0.1%, The DAX, was up by 0.2% while the CAC 40 was down by 0.1%.

The rupee was trading at Rs 67.84 against the US$ in the afternoon session. Oil prices were trading at US$ 71.27 at the time of writing.

In news from the auto sector. According to a leading financial daily, the government is set to bring in a host of measures to promote the adaptation of electric vehicles in India.

The government has plans to set up charging stations for electric vehicles every three kilometers in cities with million-plus population and smart cities, and every 50 km on busy national highways.

It is likely to offer fiscal incentives and facilitate land from municipal authorities for those interested in setting up the infrastructure, which is a key requirement for the proliferation of electric vehicles.

The government estimates that 30,000 slow charging and 15,000 fast-charging stations will be required to be put up in a phase-wise manner in the next 3-5 years.

Public sector undertakings in the energy sector such as NTPC, Power Grid Corp and Indian Oil Corp are likely to initiate the process to set up charging stations at several locations in identified cities. The government is considering providing subsidies to the PSUs for the roll out programme.

Currently, electric vehicle sales are low in India, rising 37.5% to 22,000 units in the year ended 31 March 2016 from 16,000 in 2014-15. Only 2,000 of these were cars and other four-wheelers, according to automobile lobby group Society of Indian Automobile Manufacturers (Siam).

The government wants to see 6 million electric and hybrid vehicles on Indian roads by 2020 under the National Electric Mobility Mission Plan 2020.

Is India Prepared to Meet the Ambitious Battery Car Target?

The government is targeting to have all cars propelled by electric engine by 2030. The target is more daunting than in many advanced countries.

According to the industry, the 2030 target would require eight to ten times the global stock of such vehicles. India would need to sell more than 10 million electric cars in 2030, compared to 5,000 electric vehicles India had on the road in 2016.

As you can see from the chart above, India is barely visible compared to other developed countries when it comes to battery cars.

As an article in Business Standard suggests, such a big jump in scale for the auto industry in 13 years seems difficult. The basic infrastructure is missing. There are not enough charging stations. For this massive shift, the charging stations will need to be as ubiquitous as petrol pumps.

Another issue is the price of the lithium ion battery, which constitutes 30% to 40% of the cost of the car. For this plan to succeed, the price of the battery needs to come down.

The auto industry is already facing regulatory headwinds. The shift from BS-IV emission norms to BS-VI has been two years ahead of schedule without an intermediate stage. The government, if it is serious about such ambitious targets, should offer the necessary infrastructure support and do its bit for a smooth transition.

The pharma major launched a generic version of Seretide Accuhaler, used to treat asthma, in Denmark.

The product was developed by Celon Pharma and Glenmark has marketing and distribution rights for the product across 15 European countries. This is Glenmark's first inhaled respiratory product launch in Europe. Glenmark is the first generic company to receive regulatory approval for substitution in Denmark.

There was a time when almost every stock in the pharma sector was considered to be a safe stock. You could just pick the top 5-6 companies from this sector and expect to make decent returns over time.

In fact, it was termed as defensive sector. However, in last two years things have changed a lot. There is enormous uncertainty in the industry.

Uncertainty regarding price erosion in the United States as well as hostile US FDA visits, have changed a once defensive sector into a risky sector.

However, we believe this could be point of consolidation in the industry i.e. with stricter norms, lower margins, and pricing pressure, the industry may see many exits and acquisitions. This could lead to relatively fewer but higher quality players.

We believe, if you can pick a niche company with good financials and strong management, this is a good time to consider pharma stocks.

And here's a note from Profit Hunter:

The massive fraud at the PNB, in conjunction with the diamond merchant Nirav Modi, has put the spotlight on the bank. The quaterly result has put an additional pressure on the stock price.

Last time we saw the stock breaking an important support level of 135. This indicated weakness in the counter. As a result, the stock touched a 52-week low of 91 in March 2018. It traded sideways for about two months before breaking the 91 level last week.

Today, it's nearly 12% lower with strong volumes to touch a new 52-week low of 74.

The stock is now very close to the February 2016 low of 70, which had then acted as a strong support from where it started its uptrend.

So can the stock again find ground at the 70 level or will the negative sentiment drag it even lower? It will be interesting to see how the stock reacts at this level...Keep it on your radar.

Stock Market Updates

CITY UNION BANK share price has surged by 5% and its current market price is Rs 185. The BSE BANKEX is up by 1.0%. The top gainers in the BSE BANKEX Index is CITY UNION BANK (up 5.1%). The top losers are SBI (down 0.1%) and HDFC BANK (down 0.1%).

PFIZER share price has hit an all time high at Rs 2,910 (up 1.7%). The BSE HEALTHCARE Index is up by 2.2%. Among the top gainers in the BSE HEALTHCARE Index today are PFIZER (up 1.7%) and SANOFI INDIA (up 0.2%). The top losers include NARAYANA HRUDAYALAYA LTD (down 0.2%) and GLENMARK PHARMA (down 0.3%).

NIIT TECHNOLOGIES share price has hit an all time high at Rs 1,334 (up 3.3%). The BSE IT Index is up by 0.8%. Among the top gainers in the BSE IT Index today are NIIT TECHNOLOGIES (up 3.3%) and ORACLE FINANCIAL SERVICES (up 2.3%). The top losers include MPHASIS LTD (down 0.2%) and ZENSAR TECHNOLOGIES (down 0.7%).

JSW STEEL share price has hit an all time high at Rs 350 (down 0.2%). The BSE METAL Index is up by 0.2%. Among the top gainers in the BSE METAL Index today are JSW STEEL (down 1.4%) and TATA STEEL (up 1.4%). The top losers include JSW STEEL (down 0.2%) and VEDANTA LTD (down 0.3%).

DABUR share price has hit an all time high at Rs 453 (up 2.5%). The BSE FMCG Index is up by 0.7%. Among the top gainers in the BSE FMCG Index today are DABUR (up 2.5%) and NESTLE (up 0.7%). The top losers include BOMBAY BURMAH (down 0.2%) and RADICO KHAITAN (down 0.3%).

OTHER USEFUL LINKS

MARKET STATS

ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.